Table 1.

Comparison of percentages of putative CSC populations between the two tumor types. Top: comparison of the OSA and melanoma tumor cell lines, bottom: comparison of ex vivo OSA tumor biopsies and melanoma FNAs.

Marker	OSA-average	OSA-min/max	Mel-average	Mel-min/max	p-Value
Cell line analysis
CD44	94.7%	81.9–99.6%	99.5%	98.7–99.9%	0.04*
CD34	0.1%	0–0.5%	0.6%	0.02–2.4%	0.06
CD24	0.2%	0–0.6%	0.2%	0.1–0.5%	0.52
CD133	0.07%	0–0.2%	0.06%	0.02–0.1%	0.94
CD90	47.9%	0.4–96.9%	81.8%	31.8–98.9%	0.31
Oct 3/4	0.6%	0–1.1%	1.3%	0.8–2.3%	0.03**
ALDH	0.5%	0–2.3%	13.2%	0–89%	0.80
Tumor biopsy analysis
CD44	23.5%	9.3–43.8%	32%	0.1–73.4%	0.77
CD34	4.4%	0.6–14.6%	1.7%	0.02–3.6%	0.12
CD24	1.1%	0.1–3.4%	3.4%	0.02–9.3%	0.38
CD133	0.9%	0.02–1.2%	2.2%	0.1–7.8	0.44
CD90	12%	1.5–30%	8.8%	0.06–41.6	0.05*
Oct 3/4	1.3%	0.1–11.7%	3.5%	0.4–7.9%	0.006*
ALDH	2.2%	0.01–9.2%	1.3%	0.3–3.2%	0.79

^*Statistically significant (p ≥ 0.05).